FIG. 1

Reduction in HSV1 infectivity after treatment with various concentrations of apoE derived peptides




FIG. 2

Reduction in HSV2 infectivity after treatment with various concentrations of apoE derived peptides




FIG. 3

Reduction in HIV infectivity after treatment with various concentrations of apoE derived peptides




FIG. 4

Reduction in HSV1 infectivity after treatment with various concentrations of apoE derived peptides




FIG. 5

Reduction in HSV1 infectivity after treatment with various concentrations of apoEderived peptides





FIG. 6

Reduction in HSV1 infectivity after treatment with various concentrations of apoE derived peptides



<u>FIG. 7</u>

Reduction in HSV1 infectivity after treatment with various concentrations of GIN peptides




FIG. 8

Reduction in HIV infectivity after treatment of NP2 glioma cells with various concentrations of GIN peptides




FIG. 9




Fig. 10

